Previous 10 | Next 10 |
Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold Canada NewsWire DUBLIN , Jan. 10, 2022 /CNW/ -- The campaign features real Dupuytren's contracture (DC) patients and aims to address patient ...
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution Canada NewsWire DUBLIN , Jan. 4, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun...
Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference Canada NewsWire DUBLIN , Jan. 4, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tu...
Eagle Pharmaceuticals (EGRX -0.2%) received 180 days of marketing exclusivity from the the U.S. Food and Drug Administration for its recently approved generic version of Endo International's (ENDP -1.5%) Vasostrict (vasopressin). Earlier in December, Eagle noted that that ...
Endo (ENDP +2.8%) will pay $63M to Texas as part of a settlement over accusations from the state that it played a role in the prescription opioid epidemic. Endo has not admitted any wrongdoing or fault. The money will go into the Texas State Qualified Settlement Fund. Texas has also reached o...
Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims Canada NewsWire DUBLIN , Dec. 23, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc....
Endo International's (NASDAQ:ENDP) subsidiary Endo Ventures Limited has entered into agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of XCOPRI (cenobamate) on an exclusive basis in Canada. ENDP shares up 2.9% premarket...
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada Canada NewsWire DUBLIN , Dec. 23, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limi...
In denying a Citizen Petition from Endo International (ENDP -12.4%) that sought to block approval of a generic of one of its drugs, the FDA says it is referring the company's attempt to the attention of the Federal Trade Commission. The petition "appears to have been submitted with the primar...
Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 mil...
News, Short Squeeze, Breakout and More Instantly...
Endo International plc Company Name:
ENDP Stock Symbol:
NASDAQ Market:
Endo International plc Website:
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting Canada NewsWire DUBLIN , Sept. 21, 2023 /CNW/ -- Endo International plc (OTC:...
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS Canada NewsWire DUBLIN , Aug. 8, 2023 /CNW/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023 . SECOND-QUARTER FINANCIAL PERF...
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Canada NewsWire The ready-to-use pre-filled syringe combines two well-known, FDA-approved product...